Johnson & Johnson (JNJ) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Strong cashflow ⢠Tight liquidity Johnson & Johnson delivers strong profitability, cash generation and low leverage that support dividends and R&D, but tight nearâterm liquidity and concentrated intangibles are key balanceâsheet risks that limit upside.
Price Behavior
Key Price Behavior Insights: ⢠Mild uptrend ⢠Range-bound action ⢠Failed breakout Support Level: $235.00 Resistance Level: $244.00 JNJ has mild upward momentum over the last month, trading in a ~ $235â$244 range with a quick rebound from $235 but failure to close above $244 cautioning against a decisive breakout.
Sentiment & News
Key News Insights: ⢠Icotyde approval ⢠Dividend & credit ⢠Technical momentum JNJ has re-rated from a defensive dividend stalwart into a potential growth storyâfueled by accelerated pipeline progress and early approvals (notably Icotyde with ~$8B peak-sales potential), sustained technical strength and institutional inflows, though patent/legal risks remain.
AI Summary
JNJ has shifted from a defensive, dividend-first conglomerate to a growth-with-defensive-cash-flows storyâdriven by highâconviction biologic and cellâtherapy launches plus potential DePuy proceedsâwhich makes nearâterm upside contingent on execution (monitor quarterly FCF, launch revenue cadence, and timely DePuy redeployment), while pricing pressure and large intangibles create the key downside risks if launches disappoint.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 23 | Jan 30 | JNJ | Johnson & Johnson | Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026. | Closed | +3.2% |
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |